Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
PathCentral announced that Johns Hopkins University School of Medicine’s Department of Pathology will participate as a client in the PathCentral Pathology Network (www.pathcentralpro.net), a comprehensive online information exchange and digital consultation forum.
MDxHealth announced data showing that methylation of the DCR1 gene may help guide oncologists in selecting metastatic colorectal cancer patients to receive irinotecan-based therapy. The data, presented at this year’s ASCO meeting, showed that CRC patients with methylated DCR1 did not benefit from the addition of irinotecan to capecitabine therapy.
EKF Diagnostics’ Stat-Site M Hgb is a portable hemoglobin photometer. The pocket-sized device provides accurate hemoglobin analysis results within 30 seconds from 15 µL of whole blood.
Siemens Healthcare Diagnostics will collaborate with Janssen Pharmaceutica to design, develop, and commercialize a companion diagnostic test associated with an early-stage compound Janssen is developing that targets autoantibodies directed against the human β1-adrenergic receptor that may contribute to the development of heart failure.
Sysmex America was awarded a five-year Cost Per Reportable Result agreement with VA Midwest Health Care Network (VISN 23), a Veteran Integrated Service Network.
Qiagen and SIP Biotech Development have opened the Qiagen (Suzhou) Translational Medicine Center, which aims to accelerate the discovery and validation of biomarkers and to create companion diagnostics for the Chinese market. Qiagen (Suzhou) is a joint venture of Qiagen and BioBay, a life sciences cluster in Suzhou Industrial Park, near Shanghai.
Streck’s Retic-Chex Linearity, designed to establish the patient reticulocyte reportable range and linearity, is now assayed for the Sysmex XN series (XN-10 and XN-20) hematology instruments.
General Data has acquired Triangle Biomedical Sciences. TBS will become a division of General Data Healthcare, which provides specialty products and solutions to hospitals, independent labs, and other health care facilities.
Sarstedt’s S-Monovette blood collection system enables a gentle aspiration draw with no sample transfer.
Chembio Diagnostics’ Sure Check HIV 1/2 assay has received CE Mark approval. The assay is now cleared for commercialization within the EU for rapid point-of-care detection of HIV. The product is FDA approved and distributed in the United States as Clearview Complete HIV 1/2 by Alere.
